Duvelisib was the 2nd PI3K inhibitor accepted from the FDA, also based on a section III randomized trial.130 The efficacy and protection profile on the drug seem comparable with All those of idelalisib, if not a bit advantageous. With regards to option BTK inhibitors, there are several solutions in development, but only acalabrutinib is accredited